Early Active Treatment Strategies Improve Outcomes in Newly Diagnosed High-Risk Myelodysplastic Syndrome
Researchers sought to determine whether early treatment strategies would be beneficial in patients with newly diagnosed, high-risk MDS.
Researchers sought to determine whether early treatment strategies would be beneficial in patients with newly diagnosed, high-risk MDS.
Posoleucel appears safe and effective for treating refractory viral infections occurring after allogeneic hematopoietic stem cell transplant.
Researchers sought to verify the association of mutations in the splicing pathway gene SF3B1 with low bone marrow blast counts and increased ring sideroblasts in MDS.
Lenalidomide increases the risk of developing a second primary malignancy in patients with multiple myeloma, a meta-analysis suggests.
Researchers sought to determine whether there would be a difference in outcomes for patients with lower-risk MDS with either a 5- or 7-day dosing schedule of azacitidine.
Researchers sought to determine whether azacitidine plus venetoclax would be effective in patients with high-risk MDS or chronic myelomonocytic leukemia.
Researchers sought to determine whether an online educational program regarding myelodysplastic syndromes would provide benefits to learners’ understanding of MDS.
Illegitimate online pharmacies are selling imatinib without a prescription, making false claims about being registered with regulatory bodies, and failing to provide patients with drug-related warnings.
Researchers sought to determine the role of fibrinogen levels in patients with myelodysplastic syndrome.
Researchers sought to develop a clinical risk model for predicting survival outcomes with allogeneic transplantation in patients with MDS.